Zentalis Pharmaceuticals
ZNTL
ZNTL
99 hedge funds and large institutions have $79.7M invested in Zentalis Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 36 increasing their positions, 34 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
15% less funds holding
Funds holding: 117 → 99 (-18)
42% less call options, than puts
Call options by funds: $65K | Put options by funds: $112K
82% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 22
Holders
99
Holding in Top 10
2
Calls
$65K
Puts
$112K
Top Buyers
| 1 | +$2.44M | |
| 2 | +$1.26M | |
| 3 | +$1.2M | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$609K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$521K |
Top Sellers
| 1 | -$3.89M | |
| 2 | -$2.43M | |
| 3 | -$1.72M | |
| 4 |
TCM
Tybourne Capital Management
Hong Kong
|
-$780K |
| 5 |
Goldman Sachs
New York
|
-$780K |
